From GlobeNewswire: 2025-05-08 08:02:00

Arcadia Biosciences reports a 22% increase in revenues, with Zola® sales up 90%. The company also sold patents for $750K and cut $1M in liabilities. An agreement with Roosevelt was amended to ensure a fixed equity share ratio post-merger, aiming for completion by summer’s end pending shareholder approval.

Financials for the first quarter of 2025 show a 22% revenue increase driven by Zola coconut water sales. Operating expenses dropped by $1.9M, with a $2.6M net income for stockholders. A conference call is set to discuss these results and key achievements. Details are in the SEC filings and on the company’s website.

Arcadia Biosciences continues to innovate plant-based products, delivering healthier choices to consumers. The company’s forward-looking statements are subject to risks and uncertainties. A business combination with Roosevelt Resources is in progress, with an all-stock transaction planned. Interested investors can access detailed information through SEC filings and the company’s website.



Read more at GlobeNewswire:: Arcadia Biosciences (RKDA) Announces First Quarter